Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | Using reverse engineering to create biosimilars

Mark Verrill • 29 Mar 2017
BSH 2017

Mark Verrill, MA, MB, BChir, FRCP from The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK speaks about the process of developing a biosimilar. Biosimilars are developed through the reverse engineering of an originator drug; however, the finished agent is not identical to the originator. Therefore, the biosimilar has to be extensively tested using different analytical assays to ensure that it is chemically indistinguishable from the originator product. The safety legislations ensure that clinicians also monitor the effect after the biosimilar has been released into the market to certify that patient outcomes are not different. This interview was recorded at the 2017 British Society for Hematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

More from Mark Verrill

1:47
The use of trastuzumab and biosimilars in the treatment of breast cancer
Mark Verrill • 27 Mar 2017
1:42
Advantages of using biosimilars
Mark Verrill • 27 Mar 2017
2:39
Biosimilars: breaking down barriers of prejudice
Mark Verrill • 29 Mar 2017
The content of VJHemOnc is intended for healthcare professionals